https://vettapharma.com/subscribe/subscribe-to-the-vettapharma-newsletter-for-the-latest-pharmaceutical-news-research-insights-and-ai-driven-advancements-write-to-us-at-subscribevettapharma-com-2/ 2026-04-30T07:48:41Z VETTAPHARMA en Subscribe to the VETTAPHARMA newsletter for the latest pharmaceutical news, research insights, and AI-driven advancements. Write to us at: Subscribe@vettapharma.com 2026-04-30T07:48:37Z Blog https://vettapharma.com/featured-scientific-stories/can-targeting-multiple-toxic-proteins-finally-shift-alzheimers-treatment-outcomes/ 2026-04-30T07:42:44Z VETTAPHARMA en Can Targeting Multiple Toxic Proteins Finally Shift Alzheimer’s Treatment Outcomes? 2026-04-30T07:42:39Z Blog https://vettapharma.com/pharmaceutical-news/gsk-q1-2026-results-7-6b-turnover-and-core-profit-growth/ 2026-04-30T07:03:52Z VETTAPHARMA en GSK Q1 2026 Results: £7.6B Turnover and Core Profit Growth 2026-04-30T07:03:47Z Blog https://vettapharma.com/pharmaceutical-news/fda-infant-formula-testing-confirms-safety-with-over-300-samples-analyzed/ 2026-04-30T06:48:13Z VETTAPHARMA en FDA infant formula testing confirms safety with over 300 samples analyzed 2026-04-30T06:48:08Z Blog https://vettapharma.com/pharmaceutical-news/csl-showcases-stable-leadership-as-pharma-industry-sees-ceo-shake-ups-including-sanofis-executive-overhaul-2/ 2026-04-30T06:37:31Z VETTAPHARMA en CSL Showcases Stable Leadership as Pharma Industry Sees CEO Shake-Ups, Including Sanofi’s Executive Overhaul 2026-04-30T06:37:26Z Blog https://vettapharma.com/pharmaceutical-news/novartis-q1-2026-performance-driven-by-growth-brands-pipeline-and-strategic-focus/ 2026-04-29T07:21:00Z VETTAPHARMA en Novartis Q1 2026 performance driven by growth brands pipeline and strategic focus 2026-04-29T07:20:56Z Blog https://vettapharma.com/pharmaceutical-news/astrazeneca-q1-2026-revenue-surpasses-15-billion-driven-by-strong-growth/ 2026-04-29T06:55:22Z VETTAPHARMA en AstraZeneca Q1 2026 revenue surpasses $15 billion driven by strong growth 2026-04-29T06:55:16Z Blog